Skip to content

Multicenter, not-for-profit study to evaluate tolerability, safety of tramadol once-a-day in older patients with dementia and difficulty to verbalize - NPTRAM1108

Multicenter, not-for-profit study to evaluate tolerability, safety of tramadol once-a-day in older patients with dementia and difficulty to verbalize - NPTRAM1108

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-007405-37-IT
Enrollment
Unknown
Registered
2008-12-17
Start date
2009-03-07
Completion date
Unknown
Last updated
2014-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain in older patients with dementia MedDRA version: 9.1 Level: LLT Classification code 10050533 Term: Pain assessment MedDRA version: 9.1 Level: LLT Classification code 10000428 Term: Ache NOS

Interventions

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Age ≤75 years A diagnosis of dementia of any type Difficulty to verbalize Persistent pain as testified by a score >5 at the DOLOPLUS-2 scale Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Participation to other studies in the last 3 months Refuse or inability to give consent Terminal state On an analgesic medication for over 1 month Clinical evidence suggesting an acute pain condition of any intensity Contraindication to tramadol once-a-day Epilepsy or current pharmacologic treatment with carbamazepine Juvenile intellectual disability Concomitant treatment with MAO inhibitors Presence of any disease or condition which at investigators? judgment might interfere with the study

Design outcomes

Primary

MeasureTime frame
Main Objective: Efficacy ? pain intensity, pain interference, pain relieve, physical performance, functional status;Secondary Objective: Tolerability - blood pressure, creatinine clearance, anemia, adverse events;Primary end point(s): Efficacy ? pain intensity, pain interference, pain relieve, physical performance, functional status

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026